Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Hepatologists Challenge Cochrane on Hep C DAAs

Am J Gastroenterol; ePub 2017 Nov 14; Kwo, et al

The recent Cochrane review that concluded there is no evidence to show direct acting antiviral drugs (DAAs) improve clinical outcomes in hepatitis C is incorrect, according to 3 prominent hepatologists from Stanford University, Bon Secours Liver Institute, and North Shore Long Island Jewish Health Care System.

  • The Cochrane review admitted that DAAs have a powerful impact on sustained virologic response (SVR), but questioned whether this marker has any clinical relevance.
  • The experts challenged that position because all the trials that evaluated the benefits of DAAs did not address any of these clinical end points, including decompensation events such as ascites, encephalopathy, varices, the need for liver transplantation, and liver cancer.
  • To extrapolate from the existing studies that the drugs do not offer any clinical benefits when the trials were never designed to measure these outcomes is “outrageous,” say the editorialists.

Citation:

Kwo PY, Shiffman ML, Bernstein DE. The Cochrane Review conclusion for hepatitis C DAA therapies is wrong. [Published online ahead of print Nov 14, 2017]. Am J Gastroenterol. doi:10.1038/ajg.2017.420.

This Week's Must Reads

Frailty in Patients with Ascites & Hepatic Encephalopathy, Gastroenterology; ePub 2019 Jan 19; Lai, et al

DAA Therapy for HCV & Recurrence of HCC, Gastroenterology; ePub 2019 Jan 18; Singal, et al

Hypercholesterolemia & Statin Exposure in Cirrhosis, Gastroenterology; ePub 2019 Jan 18; Kaplan, et al

NAFLD as Cause of Mortality in Patients with HCC , J Clin Gastroenterol; ePub 2019 Jan 21; Hester, et al

Post-Diagnosis Statin Use & Mortality Risk in HCC, Clin Gastroenterol Hepatol; ePub 2019 Jan 6; Thrift, et al

Must Reads in Liver Disease

Risk of Advanced Liver Disease in Hispanics , Clin Gastroenterol Hepatol; ePub 2018 Dec 7; Turner, et al

Liver Stiffness Improves After HCV Antiviral Tx, Clin Gastroenterol Hepatol; 2018 Jan; Singh, et al

Prevalence of Primary Biliary Cholangitis is Growing, Clin Gastroenterol Hepatol; ePub 2017 Dec 22; Lu, et al

Hepatologists Challenge Cochrane on Hep C DAAs, Am J Gastroenterol; ePub 2017 Nov 14; Kwo, et al

CLD Patients Don’t Reach Hospice Soon Enough, Am J Gastroenterol; 2017 Nov; Fukui, et al